China approves Lilly's Kisunla for early symptomatic Alzheimer's disease treatment, expanding global market

From Nasdaq: 2024-12-17 20:26:46

The National Medical Products Administration (NMPA) in China has approved Eli Lilly and Company’s Alzheimer’s treatment, Kisunla, for adults with early symptomatic Alzheimer’s disease. Kisunla is now approved for use in the United States, Japan, Great Britain, and China, where nearly 6% of people over 65 are living with Alzheimer’s disease. This approval comes as Alzheimer’s disease is expected to affect nearly 11% of people over 65 by 2050. For more health news, visit rttnews.com.



Read more at Nasdaq: China Approves Lilly’s Kisunla For Early Symptomatic Alzheimer’s Disease Treatment